Hitachi High-Tech Corporation, headquartered in Tokyo, Japan, has entered into a strategic partnership with Invivoscribe, Inc. by undertaking a minority investment-based, third-party allotment of shares.

The partnership aims to accelerate the molecular diagnostics and precision medicine businesses of both companies by combining Invivoscribe's technology, assay and bioinformatics development, global clinical testing, and international regulatory expertise with Hitachi High-Tech's core expertise in measurement and analysis systems technologies.

Invivoscribe is a privately-held, California-based life science corporation with seven wholly-owned subsidiaries in five countries, including clinical laboratories in four countries. 

Hitachi High-Tech's Analytical & Medical Solutions Business aims to support emerging businesses in the life science and healthcare industries while building out its own in vitro diagnostics (IVD) business. This partnership is part of Hitachi High Tech's growth strategy of strengthening this molecular diagnostics business, whose mission is to contribute to the early detection and treatment of cancer, and discover new drugs, by providing molecular cancer diagnostics to all people, thereby realizing a healthy and secure society.